KUALA LUMPUR, July 26 (Bernama) -- AmbioPharm is currently expanding both manufacturing facilities in China and the United States (US), to continue its growth to meet capacity demands for late phase and commercial peptide production.
A reliable peptide contract development and manufacturing organisation (CDMO), AmbioPharm is ready to meet the needs of a global market, according to a statement.
The latest addition to the AmbioPharm Shanghai campus brings a total of approximately 35,354 square metres of manufacturing and administrative space.
The ongoing expansion includes reactors up to 5,000 litres (L) and additional purification suites. A hydrogenation facility for liquid phase peptide synthesis (LPPS) was also recently completed and fully qualified.
An additional building is currently underway featuring state-of-the-art 3,000L solid phase peptide synthesis (SPPS) and 3,000L LPPS systems and is expected to come online as early as the fourth quarter of this year.
Meanwhile, recently inspected by the Food and Drug Administration (FDA) in February this year, the AmbioPharm North Augusta campus, located in South Carolina, US, was expanded with a total of 7,670 square metres of administrative and manufacturing space.
Working in close collaboration with its Shanghai campus, it offers end-to-end peptide manufacturing for clinical and commercial applications.
To accommodate and support growth in late phase and commercial production, the company has made recent installations to this campus and also added equipment to increase US production using greener chemistry to support manufacturing.
These upgrades allow AmbioPharm to support its customers from early phase Toxicology batches through large scale commercial manufacturing, with annual production capacity up to a metric tonne.
Further information is available at https://www.ambiopharm.com.
-- BERNAMA
No comments:
Post a Comment